The 28% reduction in the primary end point of our study is similar to the reduction of 29% in the early Burr trial , although lower than the 45% reduction in SCD in the GISSI-Prevenzione trial. If we consider the subset of 236 patients who completed the duration of the trial “on treatment”, we see a similar 48% reduction in SCD (P=0.0060).